Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week!

Published on 26/04/19 at 10:27am

The Institute for Cancer Research (ICR) called for new measures to increase the speed with which patients in the UK access innovative cancer drugs, this week. The institute suggested a new approach to funding models was necessary in order to encourage innovation.

The call came as Pfizer’s head of immune-oncology joined cancer focused firm Aduro Biotech as the company’s new CMO. The move may lead to new and innovative immunotherapies. Meanwhile GSK exec Richard Saynor was named as Novartis subsidiary Sandoz’ new CEO.

In other news, J&J settled a surgical mesh case for $9.9 million as the company faces litigation over not only the mesh but asbestos contaminated baby powder and opioids too. Check out this weeks’ top ten on Pharmafile.com!  

10. ICR calls for faster access to innovative cancer drugs

The Institute of Cancer Research (ICR) has called for faster access to innovative cancer drugs in the UK.

9. Pfizer immune-oncology leader joins Aduro Biotech as new CMO

Pfizer’s vice president and head of immune-oncology clinical development has joined Aduro Biotech as the company’s new Chief Medical Officer, just three months after the firm laid of more than a third of its workforce, as it refocused its efforts on developing treatments for cancer.

8. Heart drugs show promise in stroke and dementia

Drugs for heart disease and angina have shown promise as preventative treatments for stroke and dementia, according to scientists from the University of Edinburgh.

7. China introduces new laws to ensure steady supply of drugs

China’s National Health Commission (NHC) has said it will monitor the country’s drugs market more closely in order to ensure a sufficient supply of essential medicines.

6. Eli Lilly sell Chinese rights to two antibiotics in deal worth $375 million

US firm Eli Lilly has agreed to sell the Chinese rights to two of its antibiotics, Ceclor (cefaclor) and Vancocin (vancomycin), to Chinese firm Eddingpharm in a deal worth $375 million.

5. AbbVie's Skyrizi snatches up FDA approval in moderate to severe plaque psoriasis

AbbVie has revealed that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab-rzaa) has received marketing authorisation in the US from the FDA in the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

4. Novartis reveals promising interim Phase 3 data for gene therapy Zolgensma in spinal muscular atrophy

Novartis has revealed new interim data from its Phase 3 trial investigating the efficacy of its gene therapy Zolgensma in the treatment of spinal muscular atrophy (SMA) Type 1 in patients under six months old.

3. J&J pay $9.9 million to settle surgical mesh implant case

Healthcare conglomerate Johnson & Johnson has agreed to pay $9.9 million to settle a Washington state lawsuit over the firm’s alleged misrepresentation of the risks of pelvic mesh implants.

2. Senior GSK exec Richard Saynor revealed as new Sandoz CEO

Novartis has seen a major leadership change within its business, as the company announced that senior GlaxoSmithKline exec Richard Saynor would be stepping up to lead Sandoz, its biosimilars and generics division, as CEO from no later than 1 August.

1. Working Life: Dr Todd Hobbs, Vice President and Chief Medical Officer, Novo Nordisk

Novo Nordisk's VP and CMO discusses his leap from family medicine into the pharma industry, his biggest achievements, and how having diabetes himself has shaped his outlook on treatment throughout his career.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches